Pacific Biosciences of California(US:PACB) ZACKS·2025-10-28 23:16Company Performance - Pacific Biosciences of California (PACB) stock decreased by 5.74% to $1.97, underperforming the S&P 500's daily gain of 0.23% [1] - The stock has increased by 67.2% over the past month, outperforming the Medical sector's gain of 5.57% and the S&P 500's gain of 3.57% [1] Earnings Expectations - The company is expected to report earnings on November 5, 2025, with an estimated EPS of -$0.16, reflecting a 5.88% increase from the prior-year quarter [2] - Quarterly revenue is projected to be $39.84 million, down 0.33% from the same period last year [2] Annual Estimates - For the annual period, the Zacks Consensus Estimates predict an EPS of -$0.56 and revenue of $158.66 million, indicating increases of 32.53% and 3.02% respectively from the previous year [3] - Recent changes in analyst estimates suggest a positive outlook for the company's business and profitability [3] Zacks Rank and Industry Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently places Pacific Biosciences at 3 (Hold) [5] - The Medical - Instruments industry has a Zacks Industry Rank of 91, placing it in the top 37% of over 250 industries, indicating strong performance potential [6]